We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > V114

News List

Merck Announces Positive Topline Results from Investigational 15-valent Pneumococcal Conjugate Vaccine americanpharmaceuticalreview
May 24, 2021
Merck has announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 Phase 3 pediatric clinical program.
FDA accepts priority review of Merck’s pneumococcal vaccine pharmaceutical-technology
January 14, 2021
The US Food and Drug Administration (FDA) has accepted priority review of the Biologics License Application (BLA) of Merck’s investigational 15-valent pneumococcal conjugate vaccine candidate, V114, for preventing invasive pneumococcal disease in adults.